Stock SANOFI SANOFI INDIA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sanofi India Limited

Equities

SANOFI

INE058A01010

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:52 2024-07-03 am EDT 		5-day change 1st Jan Change
6,592 INR -0.10% Intraday chart for Sanofi India Limited -3.04% -18.29%
03:17pm Sanofi India Limited Announces Resignation of Shalini Menon, General Medicines Medical Head and India Medical Lead, Effective July 5, 2024 CI
Jun. 21 Sanofi India Limited Appoints N. Suresh Babu as Sales & Customer Engagement Head ­Diabetes, Effective July 1, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 161,572 191,565 181,781 134,721 185,790 151,811 -
Enterprise Value (EV) 1 161,572 191,565 181,781 134,721 185,790 151,811 151,811
P/E ratio 39 x 40.1 x 19.2 x 21.7 x 30.8 x 25.5 x 22.6 x
Yield 1.51% 4.39% 6.21% 9.74% - 2.62% 3.06%
Capitalization / Revenue 5.26 x 6.6 x 6.15 x 4.86 x 6.52 x 5.45 x 4.84 x
EV / Revenue 5.26 x 6.6 x 6.15 x 4.86 x 6.52 x 5.45 x 4.84 x
EV / EBITDA 24.3 x 26.9 x 23.8 x 19.1 x 23.1 x 18.4 x 16.5 x
EV / FCF 48 x 33.6 x 33.9 x 35.8 x 94.5 x 21.5 x 20.4 x
FCF Yield 2.08% 2.97% 2.95% 2.79% 1.06% 4.65% 4.91%
Price to Book 6.61 x 9.03 x 8.16 x 10.5 x 18.3 x 10.3 x 8.27 x
Nbr of stocks (in thousands) 23,031 23,031 23,031 23,031 23,031 23,031 -
Reference price 2 7,016 8,318 7,893 5,850 8,067 6,598 6,598
Announcement Date 2/25/20 2/23/21 2/23/22 2/23/23 2/23/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 30,706 29,019 29,566 27,701 28,511 27,872 31,370
EBITDA 1 6,653 7,131 7,625 7,044 8,040 8,232 9,192
EBIT 1 5,654 6,309 6,958 6,625 7,644 8,942 9,909
Operating Margin 18.41% 21.74% 23.53% 23.92% 26.81% 32.08% 31.59%
Earnings before Tax (EBT) 1 5,999 6,772 12,576 8,643 8,458 8,196 9,359
Net income 1 4,142 4,776 9,444 6,206 6,032 5,891 6,733
Net margin 13.49% 16.46% 31.94% 22.4% 21.16% 21.14% 21.46%
EPS 2 179.8 207.4 410.1 269.5 261.9 258.7 291.7
Free Cash Flow 1 3,365 5,697 5,358 3,765 1,965 7,064 7,449
FCF margin 10.96% 19.63% 18.12% 13.59% 6.89% 25.34% 23.75%
FCF Conversion (EBITDA) 50.58% 79.89% 70.27% 53.45% 24.44% 85.81% 81.04%
FCF Conversion (Net income) 81.24% 119.28% 56.73% 60.67% 32.58% 119.91% 110.63%
Dividend per Share 2 106.0 365.0 490.0 570.0 - 173.0 201.7
Announcement Date 2/25/20 2/23/21 2/23/22 2/23/23 2/23/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q3
Net sales 1 7,545 6,879 7,070 6,993 6,919 6,719 7,365 7,061 7,146 6,939 7,324 -
EBITDA 1 1,988 1,272 1,945 1,611 1,819 1,669 2,299 1,782 2,085 1,874 2,189 -
EBIT - - - - - - - - - - - 1,863
Operating Margin - - - - - - - - - - - -
Earnings before Tax (EBT) - - - - - - - - - - - -
Net income 1 5,298 904 2,384 1,204 1,824 1,309 - 1,229 2,101 1,377 1,366 -
Net margin 70.22% 13.14% 33.72% 17.22% 26.36% 19.48% - 17.41% 29.4% 19.84% 18.65% -
EPS - - - - 56.84 - - - 66.08 - - -
Dividend per Share - - - - - - - - - - - -
Announcement Date 10/26/21 2/23/22 4/26/22 7/26/22 11/3/22 2/23/23 5/10/23 8/10/23 11/8/23 2/23/24 5/13/24 -
1INR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 3,365 5,697 5,358 3,765 1,965 7,064 7,449
ROE (net income / shareholders' equity) 17.8% 20.9% 26.6% 30% 51.5% 52.4% 45.8%
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 2 1,062 921.0 968.0 555.0 442.0 641.0 798.0
Cash Flow per Share - - - - - - -
Capex 1 758 414 230 222 343 775 627
Capex / Sales 2.47% 1.43% 0.78% 0.8% 1.2% 2.78% 2%
Announcement Date 2/25/20 2/23/21 2/23/22 2/23/23 2/23/24 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Sanofi India Limited

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
SANOFI INDIA LIMITED Stock Sanofi India Limited
-18.29% 1.82B
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+21.80% 43.81B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+30.40% 23.03B
SANDOZ GROUP AG Stock Sandoz Group AG
+21.32% 15.45B
CIPLA LIMITED Stock Cipla Limited
+19.05% 14.4B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+58.92% 12.95B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-11.84% 6.49B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+13.00% 5.49B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SANOFI Stock
  4. Financials Sanofi India Limited